肺动脉高压患者的运动耐受性为什么要纳入病情评估中?

2022-03-23 刘少飞 MedSci原创

无论病因如何,运动耐量的评估都必须纳入 PH 患者的评估中。毫无疑问,它的诊断和预后作用使人们能够更深入地了解通气和循环改变,从而大大改善这种疾病的管理。

在患有慢性呼吸系统疾病的患者中,运动能力下降是影响生活质量和影响日常生活活动的常见特征。这种不耐受是由参与运动的一些生理系统功能障碍引起的,并且与呼吸困难等更严重的症状有关。从生理学的角度来看,导致不耐受运动的机制包括通气障碍、气体交换、全身和/或肺血流动力学限制以及骨骼肌异常。

肺动脉高压 (PH) 是一种血流动力学疾病,其特征是平均肺动脉压异常升高超过 20 mmHg,且静息时肺血管阻力超过 3 个伍德单位。运动能力的评估可为PH4的诊断、治疗和预后提供有价值的信息。尽管 PH 有不同的原因,但它们都有心脏循环障碍,因此评估有氧能力的测试是其诊断和随访的重要补充。

运动能力下降是PH的共同特征。因此,它是疾病临床评估中的一个重要方面。评估 PH 运动能力的最常见方法是通过六分钟步行测试 (6MWT),这是一种易于执行、价格低廉且广泛用于临床实践的次最大测试。该测试可用于评估干预的效果并提供预后信息, 但是,它并未告知我们有氧限制的起源。过去,6MWT 用于评估 PH 治疗的疗效,它目前被用作死亡风险多参数评估的基本要素之一。 

评估最大运动能力的另一种方法是通过心肺运动测试 (CPET),它提供有关最大运动对心血管反应的信息。该测试提供了对 6MWT 提供的补充诊断和预后信息。已经表明,在 CPET 中评估的一些参数,例如峰值耗氧量、脉搏氧和无氧阈下的 CO2 通气当量 (VE/VCO2),是肺动脉高压生存的预测指标。

对于慢性肺病患者,例如慢性阻塞性肺病或弥漫性间质性肺病,CPET 有助于了解努力限制的性质。不同的研究表明,在这些慢性肺部疾病中,PH 的存在显着降低峰值耗氧量超过 4 ml/min/kg,脉搏氧耗降低约 2 ml/beat,证实潜在呼吸系统疾病的限制性通气特征增加显着的心血管限制。

在慢性血栓栓塞性疾病引起的 PH 中,可以通过手术解决,在肺动脉内膜切除术前后常规进行 6MWT 作为评估疾病严重程度、功能能力和预后的工具。甚至在 6MWT 期间步行的距离和在 CPET 中获得的 VO2 也与术后残留 PH的存在有关

意识到这种情况,欧洲心脏病学会 (ESC) 和欧洲呼吸学会 (ERS) 已将 6MWT 步行距离、CPET 中获得的峰值耗氧量和类功能状态的评估纳入风险评估。纽约心脏协会 (NYHA) 也有助于评估 PH4 患者的功能状况。

然而,运动耐量不仅用于评估 PH 患者。鉴于临床指南建议对其进行测量,纳入治疗干预的研究也将运动耐量作为评估治疗有效性时最重要的指标之一。这就是运动耐量在评估新药的有效性和安全性以及外科手术和肺康复的研究中经常出现的方式。 

简而言之,无论病因如何,运动耐量的评估都必须纳入 PH 患者的评估中。毫无疑问,它的诊断和预后作用使人们能够更深入地了解通气和循环改变,从而大大改善这种疾病的管理

 

参考文献:

Isabel Blanco, Rodrigo Torres-Castro, Joan Albert Barberà, Tolerancia al esfuerzo en la hipertensión pulmonar,
Archivos de Bronconeumología,2021,ISSN 0300-2896,https://doi.org/10.1016/j.arbres.2021.11.012.

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1808664, encodeId=6694180866452, content=<a href='/topic/show?id=eade820e7c0' target=_blank style='color:#2F92EE;'>#肺动脉高压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82077, encryptionId=eade820e7c0, topicName=肺动脉高压患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Thu May 26 01:56:39 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765178, encodeId=63481e65178d0, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Dec 05 14:56:39 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925575, encodeId=daa319255e503, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 20 13:56:39 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208439, encodeId=4d081208439c4, content=关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220403/c28a2cadf15546c9a8ac250b02625037.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Sun Apr 03 21:39:27 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417747, encodeId=8957141e747ef, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Fri Mar 25 18:56:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507374, encodeId=d7d5150e374e0, content=<a href='/topic/show?id=44909421e8d' target=_blank style='color:#2F92EE;'>#运动耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94217, encryptionId=44909421e8d, topicName=运动耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91549885697, createdName=lanyan20020089, createdTime=Fri Mar 25 18:56:39 CST 2022, time=2022-03-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1808664, encodeId=6694180866452, content=<a href='/topic/show?id=eade820e7c0' target=_blank style='color:#2F92EE;'>#肺动脉高压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82077, encryptionId=eade820e7c0, topicName=肺动脉高压患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Thu May 26 01:56:39 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765178, encodeId=63481e65178d0, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Dec 05 14:56:39 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925575, encodeId=daa319255e503, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 20 13:56:39 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208439, encodeId=4d081208439c4, content=关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220403/c28a2cadf15546c9a8ac250b02625037.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Sun Apr 03 21:39:27 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417747, encodeId=8957141e747ef, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Fri Mar 25 18:56:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507374, encodeId=d7d5150e374e0, content=<a href='/topic/show?id=44909421e8d' target=_blank style='color:#2F92EE;'>#运动耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94217, encryptionId=44909421e8d, topicName=运动耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91549885697, createdName=lanyan20020089, createdTime=Fri Mar 25 18:56:39 CST 2022, time=2022-03-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1808664, encodeId=6694180866452, content=<a href='/topic/show?id=eade820e7c0' target=_blank style='color:#2F92EE;'>#肺动脉高压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82077, encryptionId=eade820e7c0, topicName=肺动脉高压患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Thu May 26 01:56:39 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765178, encodeId=63481e65178d0, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Dec 05 14:56:39 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925575, encodeId=daa319255e503, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 20 13:56:39 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208439, encodeId=4d081208439c4, content=关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220403/c28a2cadf15546c9a8ac250b02625037.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Sun Apr 03 21:39:27 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417747, encodeId=8957141e747ef, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Fri Mar 25 18:56:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507374, encodeId=d7d5150e374e0, content=<a href='/topic/show?id=44909421e8d' target=_blank style='color:#2F92EE;'>#运动耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94217, encryptionId=44909421e8d, topicName=运动耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91549885697, createdName=lanyan20020089, createdTime=Fri Mar 25 18:56:39 CST 2022, time=2022-03-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1808664, encodeId=6694180866452, content=<a href='/topic/show?id=eade820e7c0' target=_blank style='color:#2F92EE;'>#肺动脉高压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82077, encryptionId=eade820e7c0, topicName=肺动脉高压患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Thu May 26 01:56:39 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765178, encodeId=63481e65178d0, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Dec 05 14:56:39 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925575, encodeId=daa319255e503, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 20 13:56:39 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208439, encodeId=4d081208439c4, content=关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220403/c28a2cadf15546c9a8ac250b02625037.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Sun Apr 03 21:39:27 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417747, encodeId=8957141e747ef, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Fri Mar 25 18:56:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507374, encodeId=d7d5150e374e0, content=<a href='/topic/show?id=44909421e8d' target=_blank style='color:#2F92EE;'>#运动耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94217, encryptionId=44909421e8d, topicName=运动耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91549885697, createdName=lanyan20020089, createdTime=Fri Mar 25 18:56:39 CST 2022, time=2022-03-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1808664, encodeId=6694180866452, content=<a href='/topic/show?id=eade820e7c0' target=_blank style='color:#2F92EE;'>#肺动脉高压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82077, encryptionId=eade820e7c0, topicName=肺动脉高压患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Thu May 26 01:56:39 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765178, encodeId=63481e65178d0, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Dec 05 14:56:39 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925575, encodeId=daa319255e503, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 20 13:56:39 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208439, encodeId=4d081208439c4, content=关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220403/c28a2cadf15546c9a8ac250b02625037.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Sun Apr 03 21:39:27 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417747, encodeId=8957141e747ef, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Fri Mar 25 18:56:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507374, encodeId=d7d5150e374e0, content=<a href='/topic/show?id=44909421e8d' target=_blank style='color:#2F92EE;'>#运动耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94217, encryptionId=44909421e8d, topicName=运动耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91549885697, createdName=lanyan20020089, createdTime=Fri Mar 25 18:56:39 CST 2022, time=2022-03-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1808664, encodeId=6694180866452, content=<a href='/topic/show?id=eade820e7c0' target=_blank style='color:#2F92EE;'>#肺动脉高压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82077, encryptionId=eade820e7c0, topicName=肺动脉高压患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Thu May 26 01:56:39 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765178, encodeId=63481e65178d0, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Dec 05 14:56:39 CST 2022, time=2022-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925575, encodeId=daa319255e503, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 20 13:56:39 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208439, encodeId=4d081208439c4, content=关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220403/c28a2cadf15546c9a8ac250b02625037.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Sun Apr 03 21:39:27 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417747, encodeId=8957141e747ef, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Fri Mar 25 18:56:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507374, encodeId=d7d5150e374e0, content=<a href='/topic/show?id=44909421e8d' target=_blank style='color:#2F92EE;'>#运动耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94217, encryptionId=44909421e8d, topicName=运动耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91549885697, createdName=lanyan20020089, createdTime=Fri Mar 25 18:56:39 CST 2022, time=2022-03-25, status=1, ipAttribution=)]

相关资讯

ATVB:全面认识肺动脉高压中肠-肠系膜-肺轴

肺动脉高压(PAH)期间的肠道-肠道-肺轴,特别关注寄生虫引起的PAH(Sch-PAH),并试图勾勒出病原体转位可能有助于慢性肺血管疾病发病的机制。

柳叶刀:结核病后肺动脉高压-全球卫生保健差异的案例

许多肺结核幸存者会出现残留的肺病变,横断面研究一致表明存在严重的肺损伤—包括慢性阻塞性肺病(COPD)、肺活量限制、支气管扩张和肺动脉高压。

Respirology :中国肺动脉高压的特征

关于发展中国家肺动脉高压 (PAH) 的特征和长期生存率的具有全国代表性的报告很少。当前主要风险分层的适用性和目标导向治疗的纵向变化尚未在现实​​世界中阐明。

肺动脉高压中扩张的肺动脉压迫左主干冠状动脉的综合分析

肺动脉高压 (PAH) 可导致左主干冠状动脉受压 (LMCo),但有关影响、筛查和治疗的数据有限。对 LMCo 案例的荟萃分析可以填补该主题的知识空白。

ERJ: COVID-19时代意大利肺动脉高压的悖论:疾病进展的风险即将来临?

2019 年冠状病毒病 (COVID-19) 的爆发导致对常规医疗护理的重大限制。对PAH患者进行了一项多中心全国性调查,旨在确定治理措施对PAH管理的影响以及 COVID-19患者预后不良的风险。

间质性肺病的肺动脉高压研究进展

肺循环领域的疾病治疗方法已经取得了一些进展,但 PH-ILD 治疗的持续创新直到最近才出现,主要集中在 IIP,主要集中在 IPF。